Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR21884-290] to VEGF Receptor 2
- Suitable for: WB
- Reacts with: Mouse, Rat
Product nameAnti-VEGF Receptor 2 antibody [EPR21884-290]
See all VEGF Receptor 2 primary antibodies
DescriptionRabbit monoclonal [EPR21884-290] to VEGF Receptor 2
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Mouse, Rat
Recombinant fragment within Mouse VEGF Receptor 2 aa 1-800. The exact sequence is proprietary.
Database link: P35918
- WB: Mouse and rat placenta and lung lysates; bEnd.3 whole cell lysate.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage bufferpH: 7.2
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab221679 in the following tested applications.
|WB||1/1000. Detects a band of approximately 180-230 kDa (predicted molecular weight: 152 kDa).|
FunctionReceptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
Involvement in diseaseDefects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain.
modificationsPhosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.
- Information by UniProt
- CD309 antibody
- CD309 antigen antibody
- EC 188.8.131.52 antibody
All lanes : Anti-VEGF Receptor 2 antibody [EPR21884-290] (ab221679) at 1/1000 dilution
Lane 1 : Mouse placenta lysate at 20 µg
Lane 2 : Rat placenta lysate at 20 µg
Lane 3 : Rat lung lysate at 20 µg
Lane 4 : Mouse lung lysate at 20 µg
Lane 5 : bEnd.3 (mouse brain endothelioma cell line) whole cell lysate at 10 µg
Lanes 1-4 : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Lane 5 : VeriBlot for IP Detection Reagent (HRP) (ab131366) at 1/1000 dilution
Developed using the ECL technique.
Predicted band size: 152 kDa
Observed band size: 180-230 kDa why is the actual band size different from the predicted?
Exposure time : Lanes 1-2: 3 minutes; Lane 3: 37 seconds; Lane 4: 59 seconds; Lane 5: 15 seconds
The molecular mass observed is consistent with the literature (PMID: 23354168 ; PMID: 20606037).
ab221679 has not yet been referenced specifically in any publications.